Trial Condition(s):

Atrial Fibrillation (Prevention of Stroke)

Real-Life Evidence on Stroke Prevention in SPAF (RELIEF)

Bayer Identifier:

18073

ClinicalTrials.gov Identifier:

NCT02485873

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting

Inclusion Criteria
-  Age ≥18 years on the day of the first prescription of the study drug (= index date) during study selection window
 -  Diagnosis of NVAF on start date of study or anytime during 365 days before this date
 -  Availability of follow-up at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date) 
 -  Evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window.
Exclusion Criteria
-  Patients with valvular AF
 -  Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index date
 -  Prescription of more than one OAC on the index date or switch to another OAC during the follow-up period 
 -  Prescriptions of < 15mg rivaroxaban at index date or during the follow-up period for patients in rivaroxaban cohort

Trial Summary

Enrollment Goal
8607
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design